knowledge -WSS

knowledge

author：focus 2025-09-27 17:57:28 - browse：8

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： FDA early review: GLP

knowledge

WSS

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

A preacher's new calling: Diversifying neuroscience research

Medicare Advantage overpayments discussion gets experts fired up

There's an unseen cost to disruptive road

FDA sets aggressive timeline for overhauling inspection procedures

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

focus

knowledge

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

How one medical school became remarkably diverse

Physician assistants need a new name. Here's what it should be

Walensky prepares to leave CDC — and Congress — behind

Head of FDA's diagnostics center, who led through Covid, retires

Moonlake's readout produced a cash windfall. Risks remain

STAT Virtual Event: JPM Recap, Live!

Medical leaders decry Supreme Court decision on affirmative action

Medicare bonuses could stop drug shortages under Senate plan

leisure time

Inaction leaves children at risk from dangerous chemotherapy drug

American taxpayers paid $1.8 trillion in health care costs in 2022

Study suggests new cause of Down syndrome: cells linked to aging

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Medicare Advantage overpayments discussion gets experts fired up

In shift, Texas to cover initial consult for Afghan baby's gene therapy

knowledge

hotspot

focus

focus